"The β1-selective adrenoceptor agonist dobutamine": a fallacy being perpetuated.
Dobutamine is a cardiotonic agent, developed as a racemate more than 30 years ago. The compound soon got the label "the β(1)-selective adrenoceptor agonist". However, a closer examination of the enantiomers showed that (+)-dobutamine is predominantly a β(1)- and β(2)-adrenoceptor agonist with modest selectivity whereas (-)-dobutamine is predominantly an α(1)-adrenoceptor agonist. Nevertheless, rac dobutamine is still frequently used as a tool for classification of β-adrenoceptors. This ignorance of chirality may lead to erroneous conclusions and consolidate false labels.
Bertil
B
Waldeck
D058646:Adrenergic alpha-1 Receptor Agonists / Q000737:chemistry / Q000494:pharmacology; D058665:Adrenergic beta-1 Receptor Agonists / Q000737:chemistry* / Q000494:pharmacology*; D058666:Adrenergic beta-2 Receptor Agonists / Q000737:chemistry / Q000494:pharmacology; D002316:Cardiotonic Agents / Q000737:chemistry / Q000494:pharmacology; D004280:Dobutamine / Q000737:chemistry* / Q000494:pharmacology*; D006801:Humans; D013237:Stereoisomerism
D058646:Adrenergic alpha-1 Receptor Agonists; D058665:Adrenergic beta-1 Receptor Agonists; D058666:Adrenergic beta-2 Receptor Agonists; D002316:Cardiotonic Agents; D004280:Dobutamine